5-Aminolevulinic acid Hydrochloride (Gliolan®)

DRUG3 trials

Sponsors

Universität Münster, Henry Ford Health System

Conditions

Anaplastic Astrocytoma (AA)Anaplastic Oligodendroglioma (AO)Glioblastoma (GBM)Kidney CancersUpper Tract Urothelial Carcinoma

Phase 1

Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)

CompletedNCT06665724

Universität MünsterAnaplastic Astrocytoma (AA), Anaplastic Oligodendroglioma (AO), Glioblastoma (GBM)

Start: 2025-01-27End: 2026-02-09Updated: 2026-02-27

Phase 2

Photodynamic Diagnosis of Upper Tract Urothelial Carcinoma Using Fluorescence Endoscopy and Oral 5-ALA

RecruitingNCT06948552

Henry Ford Health SystemUpper Tract Urothelial Carcinoma

Start: 2026-09-15End: 2028-01-01Target: 10Updated: 2026-09-18

Photodynamic Diagnosis of Kidney Cancer Using Fluorescence Endoscopy and Oral 5-ALA

RecruitingNCT07828704

Henry Ford Health SystemKidney Cancers

Start: 2026-09-15End: 2028-01-01Target: 10Updated: 2026-09-18

Related Papers

P07.20.B SONODYNAMIC THERAPY WITH A SINGLE NEOADJUVANT, DIFFUSE DELIVERY OF LOW-INTENSITY ULTRASOUND WITH 5-ALA IN TREATMENT NAÏVE GLIOBLASTOMA RESULTS IN TUMOR-SPECIFIC CYTOTOXIC EDEMA AND INCREASED APOPTOSIS

Neuro-Oncology2025-10-01